greeksoup/ stock research

Surgery Partners (SGRY) Q2 FY2024 earnings: revenue $762 million, up 14.2% on the year

Surgery Partners, Inc. (SGRY) reported revenue of $762 million for Q2 FY2024, the quarter ended 30 June 2024, up 14.2% on the same quarter a year earlier. Net income was -$16 million, and diluted earnings per share $-0.12. The figures are the company's own, from the 10-Q it filed with the SEC on 6 August 2024.

Revenue$762 millionup 14.2%
Net income-$16 million
Diluted EPS$-0.12
QuarterQ2 FY2024ended 30 June 2024

The quarter, against the one before and a year earlier

LineQ2 FY2024Q1 FY2024Q2 FY2023Change on the year
Revenue762717668+14.2%
Operating income84.876.097.6-13.1%
Operating margin11.1%10.6%14.6%
Income tax4.94.4-7.8n/a
Net income-15.5-12.418.9n/a
Net margin-2.0%-1.7%2.8%
Diluted EPS-$0.12-$0.10$0.15n/a
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ2 FY2024Q1 FY2024Q2 FY2023Change on the year
Operating cash flow82.840.752.1+58.9%
Capital expenditure26.921.025.8+4.3%
Free cash flow55.919.726.3+112.5%
Free cash flow margin7.3%2.7%3.9%
Cash from investing-244-83.1-71.2n/a
Cash from financing19031.7-49.0n/a
Depreciation and amortisation34.833.724.4+42.6%
Share-based compensation15.14.94.6+228.3%
Diluted shares, weighted126m126m127m-1.0%
Shares outstanding at period end127m127m126m+0.5%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ2 FY2024Q1 FY2024Q2 FY2023Change on the year
Shareholders' equity1,9521,9672,018-3.3%
Non-controlling interest1,2241,071965+26.9%
Redeemable equity442324328+34.7%
Debt3,1322,8712,570+21.9%
Operating lease liabilities258250264-2.5%
Finance lease liabilities684678504+35.7%
Total liabilities and equity7,4896,9766,621+13.1%
Goodwill4,8064,3984,236+13.5%
Cash and equivalents214185177+20.3%
Receivables523494450+16.3%
Inventory80.977.070.3+15.1%
Other assets1,8641,8221,687+10.5%
Total assets7,4896,9766,621+13.1%

Questions

What was Surgery Partners' revenue in Q2 FY2024?

Surgery Partners (SGRY) reported revenue of $762 million for Q2 FY2024, the quarter ended 30 June 2024, up 14.2% on the same quarter a year earlier.

How much did Surgery Partners earn in Q2 FY2024?

Net loss for Q2 FY2024 was $16 million, and the diluted loss per share $0.12.

When did Surgery Partners report Q2 FY2024 results?

Surgery Partners filed its 10-Q for the quarter ended 30 June 2024 with the SEC on 6 August 2024.

Quarterly results, the last 20 quarters

Q3 FY2021Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue559610596615621707666668674735717762770864776826822885811849
Operating income63.611510076.574.194.246.497.682.610176.084.860.912761.911210611065.8102
Operating margin11%19%17%12%12%13%7%15%12%14%11%11%8%15%8%14%13%12%8%12%
Net income-22.9-0.112.2-18.4-25.0-23.4-24.918.9-4.9-1.0-12.4-15.5-31.7-108-37.7-2.5-22.7-15.0-35.9-15.0
Net margin-4%-0%2%-3%-4%-3%-4%3%-1%-0%-2%-2%-4%-13%-5%-0%-3%-2%-4%-2%
Diluted EPS-$0.28$0.12$0.14-$0.21-$0.28-$0.23-$0.20$0.15-$0.04-$0.01-$0.10-$0.12-$0.25-$0.86-$0.30-$0.02-$0.18-$0.12-$0.28-$0.12
Operating cash flow14.919.779.842.129.77.274.552.110562.640.782.865.21116.081.383.610311.759.3
Capital expenditure15.514.118.222.417.322.724.325.818.919.821.026.920.222.322.723.419.812.816.021.8
Free cash flow-0.65.661.619.712.4-15.550.226.385.742.819.755.945.089.1-16.757.963.890.6-4.337.5
Shares outstanding82m89m90m90m90m126m126m126m126m127m127m127m127m127m128m128m129m129m131m131m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 June 2024, filed 6 August 2024: the filing.